Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Fulcrum Therapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy) | 100K | Jan 26, 2024 | Direct | ||
Aileron Therapeutics, Inc. | Director | Stock Option (right to buy) | 35K | Dec 2, 2024 | Direct | ||
Fulcrum Therapeutics, Inc. | Chief Financial Officer | No securities are beneficially owned | 0 | Aug 7, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ALRN | Aileron Therapeutics, Inc. | Dec 2, 2024 | 1 | $0 | 4 | Dec 6, 2024 | Director |
ALRN | Aileron Therapeutics, Inc. | Aug 20, 2024 | 1 | $0 | 4 | Aug 22, 2024 | Director |
FULC | Fulcrum Therapeutics, Inc. | Jan 26, 2024 | 1 | $0 | 4 | Jan 30, 2024 | Chief Financial Officer |
FULC | Fulcrum Therapeutics, Inc. | Jan 17, 2024 | 1 | $0 | 4 | Jan 19, 2024 | Chief Financial Officer |
ALRN | AILERON THERAPEUTICS INC | Oct 31, 2023 | 1 | $0 | 4 | Nov 2, 2023 | Director |
ALRN | AILERON THERAPEUTICS INC | Oct 31, 2023 | 0 | $0 | 3 | Nov 2, 2023 | Director |
FULC | Fulcrum Therapeutics, Inc. | Aug 7, 2023 | 1 | $0 | 4 | Aug 9, 2023 | Chief Financial Officer |
FULC | Fulcrum Therapeutics, Inc. | Aug 7, 2023 | 0 | $0 | 3 | Aug 9, 2023 | Chief Financial Officer |